Cargando…
The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018
Genital warts (GWs) caused by the human papilloma virus (HPV) are a significant health problem due to high prevalence and rate of recurrence. Bivalent vaccine has been used since the start of the national vaccination program in 2013, making it feasible to study the GW burden in Finland. There is no...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384701/ https://www.ncbi.nlm.nih.gov/pubmed/37515019 http://dx.doi.org/10.3390/vaccines11071202 |
_version_ | 1785081221768806400 |
---|---|
author | Gylling, Annette Uusi-Rauva, Kristiina Toppila, Iiro Hiltunen-Back, Eija |
author_facet | Gylling, Annette Uusi-Rauva, Kristiina Toppila, Iiro Hiltunen-Back, Eija |
author_sort | Gylling, Annette |
collection | PubMed |
description | Genital warts (GWs) caused by the human papilloma virus (HPV) are a significant health problem due to high prevalence and rate of recurrence. Bivalent vaccine has been used since the start of the national vaccination program in 2013, making it feasible to study the GW burden in Finland. There is no national and up-to-date information available on the prevalence and the burden of GWs in the various healthcare sectors in Finland. The present study investigated the prevalence, healthcare resource use, and direct medical costs of the treatment of GWs in Finland in 2018 using data in national healthcare registers. GW cases were identified based on diagnoses in public healthcare and GW-related prescription medications. Cost analysis included public healthcare contacts, procedures in private care, and medications. The study showed that approximately 12,000 GWs cases were treated in Finland in 2018. Since less than half of GW diagnoses were recorded in public healthcare registers, determining the exact costs was challenging. The estimated direct treatment costs in 2018 were 2.6 M€, which is higher than the previous estimation in Finland, yet still likely an underestimation of the true burden. These results provide information for the management of the GW burden in Finland. |
format | Online Article Text |
id | pubmed-10384701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103847012023-07-30 The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018 Gylling, Annette Uusi-Rauva, Kristiina Toppila, Iiro Hiltunen-Back, Eija Vaccines (Basel) Article Genital warts (GWs) caused by the human papilloma virus (HPV) are a significant health problem due to high prevalence and rate of recurrence. Bivalent vaccine has been used since the start of the national vaccination program in 2013, making it feasible to study the GW burden in Finland. There is no national and up-to-date information available on the prevalence and the burden of GWs in the various healthcare sectors in Finland. The present study investigated the prevalence, healthcare resource use, and direct medical costs of the treatment of GWs in Finland in 2018 using data in national healthcare registers. GW cases were identified based on diagnoses in public healthcare and GW-related prescription medications. Cost analysis included public healthcare contacts, procedures in private care, and medications. The study showed that approximately 12,000 GWs cases were treated in Finland in 2018. Since less than half of GW diagnoses were recorded in public healthcare registers, determining the exact costs was challenging. The estimated direct treatment costs in 2018 were 2.6 M€, which is higher than the previous estimation in Finland, yet still likely an underestimation of the true burden. These results provide information for the management of the GW burden in Finland. MDPI 2023-07-05 /pmc/articles/PMC10384701/ /pubmed/37515019 http://dx.doi.org/10.3390/vaccines11071202 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gylling, Annette Uusi-Rauva, Kristiina Toppila, Iiro Hiltunen-Back, Eija The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018 |
title | The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018 |
title_full | The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018 |
title_fullStr | The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018 |
title_full_unstemmed | The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018 |
title_short | The Burden of Genital Warts in Finland: Cross-Sectional Analysis of the Prevalence and Direct Medical Costs in 2018 |
title_sort | burden of genital warts in finland: cross-sectional analysis of the prevalence and direct medical costs in 2018 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384701/ https://www.ncbi.nlm.nih.gov/pubmed/37515019 http://dx.doi.org/10.3390/vaccines11071202 |
work_keys_str_mv | AT gyllingannette theburdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018 AT uusirauvakristiina theburdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018 AT toppilaiiro theburdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018 AT hiltunenbackeija theburdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018 AT gyllingannette burdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018 AT uusirauvakristiina burdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018 AT toppilaiiro burdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018 AT hiltunenbackeija burdenofgenitalwartsinfinlandcrosssectionalanalysisoftheprevalenceanddirectmedicalcostsin2018 |